Acerand Therapeutics (Hong Kong) Limited – Trademark Portfolio

Entity Type: 16

Acerand Therapeutics (Hong Kong) Limited holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include ACERAND and ACERAND THERAPEUTICS A. The owner is based in Hong Kong.

Rm 1501-05, 15/F, FWD Financial Centre

Hong Kong , HK

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Acerand Therapeutics (Hong Kong) Limited's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Acerand Therapeutics (Hong Kong) Limited have?

Acerand Therapeutics (Hong Kong) Limited has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Acerand Therapeutics (Hong Kong) Limited file in?

Acerand Therapeutics (Hong Kong) Limited files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Acerand Therapeutics (Hong Kong) Limited's most well-known trademarks?

Acerand Therapeutics (Hong Kong) Limited's registered trademark portfolio includes well-known marks such as ACERAND and ACERAND THERAPEUTICS A. These are among 2 currently registered trademarks in the portfolio.

What is Acerand Therapeutics (Hong Kong) Limited's trademark registration success rate?

Acerand Therapeutics (Hong Kong) Limited has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.